Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064020 · ClinicalTrials.gov registry record
Bictegravir in the Elderly Living With HIV (BICEP)
A clinical trial of HIV-1-infection, sponsored by State University of New York at Buffalo.
- Active
- Registry status
- 162
- Enrollment target
- 1
- Study location
NCT05064020 is a study of HIV-1-infection that is active but no longer recruiting, run by State University of New York at Buffalo. The registered enrollment target is 162 participants, below the 349-participant average among 71 other HIV-1-infection trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05064020, a study of HIV-1-infection, is active but no longer recruiting, sponsored by State University of New York at Buffalo.
- ACTIVE NOT RECRUITING
- Registry status
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, open-label, single center, post-approval and post-marketing study. Current national guideline recommends an integrase strand inhibitors (INSTI) in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) as standard of therapy for HIV-1 infected patients. INSTI-based regimen may require a potent CYP3A inhibitor such as cobicistat to increase INSTI's plasma concentration and prolongs half-life. However, co-administration with a CYP3A inhibitor may increase the risk of drug-drug interactions. A novel INSTI, bictegravir, does not need a booster for pharmacokinetic enhancement. Hypothesis: switching HIV-1 infected patients from booster containing regimen to bictegravir based regimen would decrease the risk of drug-drug interactions caused by a booster and improve quality of life and adherence.
Conditions Studied
Interventions
- DRUG Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Study Locations (1)
New York
- Evergreen Health - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05064020
The ClinicalTrials.gov registry entry for NCT05064020 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 349-participant average among 71 other HIV-1-infection trials with a reported enrollment target (54% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY] is the first listed.
NCT05064020 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05064020 about?
NCT05064020 is a clinical study titled "Bictegravir in the Elderly Living With HIV (BICEP)". This is a prospective, open-label, single center, post-approval and post-marketing study. Current national guideline recommends an integrase strand inhibitors (INSTI) in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) as standard of therapy for HIV-1 infected patients. INSTI...
What is the current status of trial NCT05064020?
This trial is currently active not recruiting. The enrollment target is 162 participants. The study started on 2020-08-01. Estimated completion is 2024-12-31.
What conditions does trial NCT05064020 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT05064020?
The interventions under investigation include: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY] (DRUG).
Who is sponsoring clinical trial NCT05064020?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05064020 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
RECRUITING · NA
-
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
RECRUITING
-
Ending the Epidemic Interventions in the Dental Setting - UH3
RECRUITING · NA
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.